CIRI - Centre International de Recherche en Infectiologie, Univ Lyon, Université Claude Bernard Lyon 1, Inserm, U1111, CNRS, UMR5308, ENS Lyon, 46 allée d'Italie, 69007, Lyon, France.
Cancer Immunol Immunother. 2022 Jul;71(7):1771-1775. doi: 10.1007/s00262-021-03101-4. Epub 2021 Nov 8.
Here, we report a novel experimental setup to perform adoptive transfer of gene-edited B cells using humanized immune system mice by infusing autologous HIS mouse-derived human B cells "educated" in a murine context and thus rendered tolerant to the host. The present approach presents two advantages over the conventional humanized PBMC mouse models: (i) it circumvents the risk of xenogeneic graft-versus-host reaction and (ii) it mimics more closely human immune responses, thus favoring clinical translation. We show that the frequencies and numbers of transduced B cells in recipient's spleens one week post-transfer are within the range of the size of the pre-immune B cell population specific for a given protein antigen in the mouse. They are also compatible with the B cell numbers required to elicit a sizeable immune response upon immunization. Altogether, our findings pave the way for future studies aiming at assessing therapeutic interventions involving B cell reprogramming for instance by an antibody transgene in a "humanized" hematopoietic setting.
在这里,我们报告了一种新的实验设置,通过输注自体 HIS 小鼠来源的在鼠类环境中“教育”并因此对宿主耐受的人源 B 细胞,在人源化免疫系统小鼠中进行基因编辑 B 细胞的过继转移。与传统的人源化 PBMC 小鼠模型相比,本方法有两个优势:(i)它避免了异种移植物抗宿主反应的风险;(ii)它更紧密地模拟了人类免疫反应,从而有利于临床转化。我们表明,在转移后一周,受体脾脏中转导的 B 细胞的频率和数量在针对小鼠中特定蛋白质抗原的预免疫 B 细胞群体大小范围内。它们也与免疫接种时引发可观免疫反应所需的 B 细胞数量兼容。总之,我们的研究结果为未来的研究铺平了道路,这些研究旨在评估涉及 B 细胞重编程的治疗干预措施,例如通过抗体转基因在“人源化”造血环境中。